Effects of Dopaminergic and Cholinergic Drugs. Naloxone and L-prolyl-leucyl-glycinamide on LSD-induced Catalepsy

Overview

Journal Naunyn Schmiedebergs Arch Pharmacol

Specialty Pharmacology

Date 1980 Aug 1

PMID 6111027

Authors

S Chiu

R K Mishra

Affiliations

Soon will be listed here.

Abstract

In an attempt to elucidate the mechanism of d-lysergic acid diethylamide (LSD) induced catalepsy, the effects of cholinergic and dopaminergic agents, naloxone and L-propyl-leucyl-glycinamide (PLG) were studied in rats. The dose-dependent (50--500 micrograms kg-1 s.c.) and time-related cataleptic response elicited by LSD was preceded by a phase of hyperexcitability. The non-hallucinogenic analogue, 2-bromo-LSD (BOL), was without effect. Both apomorphine, the dopamine agonist, and L-DOPA antagonized LSD-induced catalepsy whereas the dopamine depleting agent alpha-methyl-p-tyrosine (alpha-MPT) slightly prolonged the cataleptic effect. Cholinergic muscarinic receptor stimulation with pilocarpine antagonized LSD-induced catalepsy. The muscarinic antagonists, atropine and scopolamine, intensified the hyperexcitable phase and potentiated the cataleptic effects of LSD. Nicotine slightly potentiated LSD action but mecamylamine antagonized it. While pre-treatment with naloxone, the narcotic antagonist and PLG prolonged the cataleptic response, post-treatment with naloxone effectively attenuated LSD-induced catalepsy. The behavioural data are interpreted to suggest that LSD-induced catalepsy may be mediated through diminished dopaminergic and cholinergic neuronal activity and under enkephalinergic modulation. The neuroanatomical foci and exact mechanism of action remain to be delineated.

References

Kaakkola S, Ahtee L . Effect of muscarinic cholinergic drugs on morphine-induced catalepsy, antinociception and changes in brain dopamine metabolism. Psychopharmacology (Berl). 1977; 52(1):7-15. DOI: 10.1007/BF00426593. View

Christoph G, Kuhn D, Jacobs B . Electrophysiological evidence for a dopaminergic action of LSD: depression of unit activity in the substantia nigra of the rat. Life Sci. 1977; 21(11):1585-96. DOI: 10.1016/0024-3205(77)90235-1. View

Corsini G, Del Zompo M, Spissu A, Mangoni A, Gessa G . Parkinsonism by haloperidol and piribedil. Psychopharmacology (Berl). 1978; 59(2):139-41. DOI: 10.1007/BF00427747. View

Muller P, Seeman P . Catalepsy induced by morphine or haloperidol: effects of apomorphine and anticholinergic drugs. Can J Physiol Pharmacol. 1976; 54(4):516-9. DOI: 10.1139/y76-071. View

Ahtee L . Effect of cholingeric drugs on methadone-induced catalepsy and stereotypies in rats treated chronically with methadone. Eur J Pharmacol. 1976; 39(2):203-13. DOI: 10.1016/0014-2999(76)90128-x. View

Pieri L, Keller H, BURKARD W, Da Prada M . Effects of lisuride and LSD on cerebral monoamine systems and hallucinosis. Nature. 1978; 272(5650):278-80. DOI: 10.1038/272278a0. View

Chiu S, Mishra R . Antagonism of morphine-induced catalepsy by L-prolyl-L-leucyl-glycinamide. Eur J Pharmacol. 1979; 53(2):119-25. DOI: 10.1016/0014-2999(79)90156-0. View

Peters D, Tang S . The effects of repeated D-lysergic acid diethylamide injections on catecholamine levels and tyrosine hydroxylase activity in rat brain regions. J Neurochem. 1977; 28(1):59-62. DOI: 10.1111/j.1471-4159.1977.tb07708.x. View

Fertziger A, Fischer R . Interaction between narcotic antagonist (naloxone) and lysergic acid diethylamide (LSD) in the rat. Psychopharmacology (Berl). 1977; 54(3):313-4. DOI: 10.1007/BF00426582. View

10.

Trulson M, Stark A, Jacobs B . Comparative effects of hallucinogenic drugs on rotational behavior in rats with unilateral 6-hydroxydopamine lesions. Eur J Pharmacol. 1977; 44(2):113-9. DOI: 10.1016/0014-2999(77)90097-8. View

11.

Persson S . The effect of LSD and 2-bromo LSD on the striatal DOPA accumulation after decarboxylase inhibition in rats. Eur J Pharmacol. 1977; 43(1):73-83. DOI: 10.1016/0014-2999(77)90162-5. View

12.

Creese I, Burt D, Snyder S . Dopamine receptor binding: differentiation of agonist and antagonist states with 3H-dopamine and 3H-haloperidol. Life Sci. 1975; 17(6):933-1001. DOI: 10.1016/0024-3205(75)90454-3. View

13.

Aghajanian G . LSD and 2-bromo-LSD: comparison on effects on serotonergic neurones and on neurones in two serotonergic projection areas, the ventral lateral geniculate and amygdala. Neuropharmacology. 1976; 15(9):521-8. DOI: 10.1016/0028-3908(76)90102-7. View

14.

Pieri L, Pieri M, Haefely W . LSD as an agonist of dopamine receptors in the striatum. Nature. 1974; 252(5484):586-8. DOI: 10.1038/252586a0. View

15.

Lovell R, Freedman D . Stereospecific receptor sites for d-lysergic acid diethylamide in rat brain: effects of neurotransmitters, amine antagonists, and other psychotropic drugs. Mol Pharmacol. 1976; 12(4):620-30. View

16.

Amenta F, Bernardi G, FLORIS V, Marciani M . Localization of alpha-bungarotoxin binding sites within the rat corpus striatum. Neuropharmacology. 1979; 18(3):319-22. DOI: 10.1016/0028-3908(79)90133-3. View

17.

Hayes R, Newlon P, ROSECRANS J, MAYER D . Reduction of stimulation-produced analgesia by lysergic acid deithylamide, a depressor of serotonergic neural activity. Brain Res. 1977; 122(2):367-72. DOI: 10.1016/0006-8993(77)90304-3. View

18.

Costall B, Naylor R . On catalepsy and catatonia and the predictability of the catalepsy test for neuroleptic activity. Psychopharmacologia. 1974; 34(3):233-41. DOI: 10.1007/BF00421964. View

19.

Plotnikoff N, Kastin A . Commentary: Neuropharmacology of hypothalamic releasing factors. Biochem Pharmacol. 1976; 25(4):363-5. DOI: 10.1016/0006-2952(76)90332-4. View

20.

Walters J, Roth R . Dopaminergic neurons: an in vivo system for measuring drug interactions with presynaptic receptors. Naunyn Schmiedebergs Arch Pharmacol. 1976; 296(1):5-14. DOI: 10.1007/BF00498834. View